Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering. The report provides insights into Bayer AG's tech activities, including its digital ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Germany is widely recognized as one of the leading countries in the pharmaceutical industry boasting a rich history of innovation cutting-edge research and global influence With its well-established i ...

Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...

The data uncover broad optimism as well as stark regional disparities and cultural obstacles in the West that must be ...

(Bloomberg) -- Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the company still faces after its $63 billion acquisition of ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...